Scientists in the United Arab Emirates have reportedly harnessed artificial intelligence to discover a potential new drug for blood cancer. This development showcases the application of AI in accelerating pharmaceutical research and drug discovery processes. The research, conducted by UAE-based institutions, aims to identify novel therapeutic compounds for critical medical conditions. Why it matters: This highlights the UAE's emerging capabilities in AI-driven healthcare innovation and its potential contribution to global medical advancements.
MBZUAI master's student Sayed Hashim is applying machine learning to improve cancer diagnosis and treatment, motivated by personal loss. He and fellow student Muhammad Ali developed algorithms for cancer type classification from multi-omics data, achieving over 96% accuracy. Their work, supervised by MBZUAI faculty, resulted in a published paper on multi-omics data representation learning. Why it matters: This research demonstrates the potential of AI and machine learning to advance cancer research and personalized medicine in the region.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
MBZUAI and GenBio AI have won the UAE AI Award 2025 in the AI Scientific Research category for their "Unified Protein Language Modeling Framework". The winning project enables AI to learn protein function, generate sequences, and predict 3D structures. The AI-driven simulation approach aims to accelerate drug development, reduce costs, and improve success rates. Why it matters: This award highlights the UAE's commitment to fostering AI innovation in biomedicine and drug discovery, positioning the region as a leader in AI-driven healthcare advancements.
MBZUAI and BioMap have signed an MoU to establish the first biocomputing innovation research lab in the Middle East, located on MBZUAI's campus. The collaboration will focus on applying AI protein generation to life science models, addressing needs in drug design, energy, and environmental protection. The lab will research de novo design of oil degradation enzymes and identify drug targets for aging-associated and rare diseases. Why it matters: This partnership signals a growing focus on applying AI to critical life science challenges in the region, potentially leading to breakthroughs in drug discovery and sustainable energy solutions.